Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus.
Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus.
This study will evaluate the anti-cancer effects of crizotinib when compared with standard chemotherapy in patients with ALK positive lung cancer.
Inclusion Criteria:
Exclusion Criteria:
Loma Linda, California 92354, United States
Washington D.C., District of Columbia 20007, United States
St Louis, Missouri 63110, United States
Dallas, Texas 75390-9015, United States
East Melbourne, Victoria 3002, Australia
São Paulo, São Paulo 01246-000, Brazil
Montreal, Quebec H4A 3J1, Canada
Ste-Foy, Quebec G1V 4G5, Canada
Independencia, Santiago, Rm 8380456, Chile
Wuhan, Hubei 430023, China
Helsinki, 00290, Finland
Marseille, 13915, France
Strasbourg, 67091, France
Ahmedabad, Gujarat 380 016, India
Aviano, Pordenone 33081, Italy
Milan, 20133, Italy
Orbassano (TO), 10043, Italy
Reggio Emilia, 42123, Italy
Osakasayama-shi, Osaka 589-8511, Japan
Sunto-gun, Shizuoka 411-8777, Japan
Chuo-Ku, Tokyo 104-0045, Japan
Koto-ku, Tokyo 135-8550, Japan
Ube-shi, Yamaguchi 755-0241, Japan
Maastricht, 6229 HX, Netherlands
Glasgow, Scotland G12 0YN, United Kingdom